King Faisal Specialist Hospital, Riyadh – United Arab Emirates
About Dr. Marwan Shaheen
Dr. Marwan Shaheen is a Consultant Adult Hematologist based in Riyadh, Saudi Arabia, specialising in chronic leukemia and myeloproliferative neoplasms. A trusted hematology specialist Riyadh, Saudi Arabia with Canadian training experience, he is a co-editor of the hospital's authoritative guidelines for the management of haematological malignancies.
- Consultant in the Chronic Leukemia / Myeloproliferative Neoplasms Section.
- Previous international training and collaboration with a leading Canadian academic cancer centre.
- Co-editor — Guidelines for the Management of Hematological Malignancies (4th Edition).
- Active role in the national CAR T-cell therapy and Saudi AML whole-genome sequencing programmes.
- Experience caring for international patients with complex chronic hematological malignancies.
Qualifications & Credentials
Medical Degrees
- MBBS
- Residency — Internal Medicine
Fellowships & Special Training
- Fellowship — Hematology / Hematologic Malignancies
- International training experience — Canadian academic medical centre
Certifications & Accreditations
- Saudi Commission for Health Specialties (SCFHS) Registration
- Member — American Society of Hematology (ASH)
- Member — European Hematology Association (EHA)
Areas of Expertise
Major Conditions Treated
- Chronic Myeloid Leukemia (CML)
- Chronic Lymphocytic Leukemia (CLL)
- Polycythemia Vera
- Essential Thrombocythemia
- Primary & Secondary Myelofibrosis
- Myelodysplastic / Myeloproliferative Overlap Syndromes
- Myelodysplastic Syndromes
- Acute Myeloid Leukemia (Core Binding Factor & Other)
- Philadelphia-Positive B-ALL
- CML in Pregnancy
Sub-specialties
- Tyrosine Kinase Inhibitor Therapy for CML: Expert in imatinib, dasatinib, nilotinib, bosutinib, and ponatinib therapy for chronic myeloid leukemia, including treatment-free remission protocols — a trusted hematology specialist Riyadh, Saudi Arabia for chronic leukemia.
- Myeloproliferative Neoplasms: Manages polycythemia vera, essential thrombocythemia, and myelofibrosis using JAK inhibitors (ruxolitinib, fedratinib), cytoreductive therapy, and HSCT referral.
- Chronic Leukemia in Special Populations: Contributor to 15-year single-centre CML-in-pregnancy cohort and core binding factor AML consolidation research.
Advanced Procedures & Treatments
- Tyrosine Kinase Inhibitor Therapy (Imatinib, Dasatinib, Nilotinib, Bosutinib, Ponatinib)
- JAK Inhibitor Therapy (Ruxolitinib, Fedratinib)
- Cytoreductive Therapy (Hydroxyurea, Interferon) for MPN
- BCL2 Inhibitor (Venetoclax) Combinations for CLL
- BTK Inhibitor Therapy for CLL
- Allogeneic HSCT Referral for Advanced MPN / MDS
- Blinatumomab with TKI for Ph-Positive B-ALL
- Molecular Monitoring for CML (BCR-ABL1 qPCR)
Professional Experience
Current Affiliation
- King Faisal Specialist Hospital & Research Centre (KFSHRC), Riyadh, Saudi Arabia — Consultant, Chronic Leukemia / Myeloproliferative Neoplasms Section, Department of Hematology, Stem Cell Transplantation and Cellular Therapy (Present)
Past Affiliations
- University of Toronto / Princess Margaret Cancer Centre, Toronto, Canada — Research and clinical training experience (Past)
Academic & Research Roles
- Faculty — KFSHRC Hematology & HSCT Fellowship Programme
- Member — KFSHRC Leukemia Multidisciplinary Tumour Board
Key Achievements
- Co-editor — Guidelines for the Management of Hematological Malignancies, KFSHRC Riyadh, 4th Edition (2015)
- Contributing investigator — Saudi AML Whole-Genome Sequencing programme
- Co-author on multi-centre research on blinatumomab + TKI for Ph+ B-ALL
- Contributor to 15-year single-centre CML in pregnancy cohort analysis
Awards & Recognitions
National & International Awards
- Information not publicly available.
Professional Memberships
- American Society of Hematology (ASH)
- European Hematology Association (EHA)
- Saudi Society of Hematology
- Eastern Mediterranean Blood and Marrow Transplantation Group (EMBMT)
Research & Publications
Published Papers (Selected)
- Almohareb F, Chaudhri N, AlSharif F, …, Al-Nahedh M. Guidelines for the Management of Hematological Malignancies — KFSHRC Riyadh (4th Edition). 2015.
- Deotare UR, Shaheen M, Brandwein JM, …, Schuh A. Predictive Value of Molecular Remissions Post Consolidation Chemotherapy in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemias — A Single Centre Analysis. 2014.
- Aleid M, Alrajhi A, …, Tailor IK, Hanbali A, Alfraih FA, …, Shaheen M, …, Aljurf M, Elfakih R, Alhumaid M, Alfayez M. Blinatumomab with Tyrosine Kinase Inhibitor for Ph-Positive B-Acute Lymphoblastic Leukemia: Multicenter Retrospective Review. Blood. 2023;142(Suppl 1):5889.
Ongoing Research & Clinical Interests
- Long-term outcomes in chronic myeloid leukemia and treatment-free remission
- Myeloproliferative neoplasms: JAK inhibitor therapy and HSCT consolidation
- Molecular monitoring and measurable residual disease in CBF AML
- Saudi Arabia AML genomics and population-specific risk profiling
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (INR) | Estimated Cost (USD) |
|---|---|---|
| Hematology Consultation | ₹1,500 – ₹3,500 | $18 – $42 |
| Bone Marrow Biopsy & Aspiration | ₹15,000 – ₹35,000 | $180 – $420 |
| Autologous Stem Cell Transplant | ₹15,00,000 – ₹22,00,000 | $18,000 – $26,500 |
| Allogeneic Stem Cell Transplant (Matched) | ₹22,00,000 – ₹35,00,000 | $26,500 – $42,000 |
| CAR T-cell Therapy | ₹1,50,00,000 – ₹3,50,00,000 | $1,80,000 – $4,20,000 |
*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.
Frequently Asked Questions
1. What advanced technologies does Dr. Marwan Shaheen use in Chronic Leukemia & Myeloproliferative Neoplasms treatment?
Dr. Marwan Shaheen uses modern hematology tools including molecular monitoring of CML by BCR-ABL1 quantitative PCR, tyrosine kinase inhibitors across first- to third-generation, JAK inhibitors (ruxolitinib, fedratinib) for myelofibrosis, BTK and BCL2 inhibitors for CLL, venetoclax-based low-intensity AML regimens, and integrated HSCT referral for high-risk disease. Cancer Rounds can coordinate virtual pre-travel consultation for international patients.
2. What conditions does Dr. Marwan Shaheen specialize in treating?
Dr. Marwan Shaheen specialises in chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), polycythemia vera, essential thrombocythemia, myelofibrosis, myelodysplastic/myeloproliferative overlap syndromes, myelodysplastic syndromes, AML, and Philadelphia-positive B-ALL — making him a trusted hematology specialist Riyadh, Saudi Arabia for best chronic leukemia and myeloproliferative neoplasm care.
3. How do I book an appointment with Dr. Marwan Shaheen?
Appointments with Dr. Marwan Shaheen can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Dr. Marwan Shaheen?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Dr. Marwan Shaheen, including medical visa invitation letters, airport transfers, and local accommodation coordination.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation, financial counselling, and pre-travel virtual consultations to review medical records before arrival.
6. Does Dr. Marwan Shaheen offer second opinions for Chronic Leukemia & Myeloproliferative Neoplasms cases?
Yes. Second opinion consultations with Dr. Marwan Shaheen can be arranged via Cancer Rounds for patients seeking an expert Chronic Leukemia and Myeloproliferative Neoplasm review of diagnosis, molecular risk-stratification, TKI selection and treatment-free remission, JAK inhibitor therapy, and HSCT candidacy in Riyadh, Saudi Arabia.
